Xilio Therapeutics, Inc.
XLO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$7.57
KIRA · Stoqly’s AI analyst, in plain words
- Xilio Therapeutics, Inc. had $43.8M of revenue in fiscal 2025, up 589.9% on the year before.
- Its operating margin was −95.9%, up 859.0 pts: of every 100 in sales, about −96 is left after running the business.
- Xilio Therapeutics, Inc. lost $35.0M in fiscal 2025.
- Free cash flow was −$5.5M in fiscal 2025, −12.6% of revenue.
Market cap
—
P/E
—
Revenue
$43.8M
Net income
−$35.0M
Free cash flow
−$5.5M
Operating margin
−95.9%
Xilio Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+589.9%
Yes. Sales grew 589.9% last year.
Does it make a profit?
−80.1%
No. It lost money last year.
Does profit turn into cash?
−12.6%
No. It spent more cash than it brought in.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Xilio Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 23, 2026
- Legal name
- Xilio Therapeutics, Inc.
- CIK
- 0001840233
Xilio Therapeutics, Inc. · XLO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | — | $6.3M | $43.8M |
| Revenue growth | — | — | — | — | 589.9% |
| Operating margin | — | — | — | −954.9% | −95.9% |
| Net income | −$75.8M | −$88.2M | −$76.4M | −$58.2M | −$35.0M |
| Net margin | — | — | — | −918.0% | −80.1% |
| Diluted EPS | −$13.52 | −$3.22 | −$2.78 | −$15.24 | −$4.19 |
| Cash | |||||
| Cash from operations | −$80.8M | −$75.7M | −$68.6M | −$18.4M | −$5.0M |
| Capital expenditure | $1.1M | $1.9M | $0.5M | $0.0M | $0.5M |
| Free cash flow | −$81.9M | −$77.6M | −$69.1M | −$18.4M | −$5.5M |
| FCF margin | — | — | — | −290.3% | −12.6% |
| Debt and strength | |||||
| Cash and short-term investments | $198M | $120M | $44.7M | $55.3M | $138M |
| Shareholders' equity | $185M | $106M | $36.8M | $17.6M | $35.3M |
| Current ratio | 15.8x | 5.9x | 3.0x | 2.2x | 2.6x |
| Returns and quality | |||||
| Return on equity | −148.4% | −60.6% | −107.3% | −214.0% | −132.5% |
| Return on tangible equity | −40.9% | −83.5% | −207.5% | −331.0% | −99.3% |
| Altman Z'' | 7.0 | −2.0 | −21.1 | −19.9 | −6.6 |
Insiders bought, 12 months
$0.0M
1 insider
Insiders sold, 12 months
$0.0M
2 insiders
Of sales under plans
100%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Xilio Therapeutics, Inc. · XLO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.57 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001840233). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.